These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 3126347)
1. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor]. Köhler M; Miyashita C Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347 [TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
3. Diurnal variation of the fibrinolytic system. Grimaudo V; Hauert J; Bachmann F; Kruithof EK Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085 [TBL] [Abstract][Full Text] [Related]
4. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814 [TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812 [TBL] [Abstract][Full Text] [Related]
6. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Kluft C; Jie AF; Rijken DC; Verheijen JH Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814 [TBL] [Abstract][Full Text] [Related]
7. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man. Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078 [TBL] [Abstract][Full Text] [Related]
8. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926 [TBL] [Abstract][Full Text] [Related]
9. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Keber D; Stegnar M; Kluft C Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049 [TBL] [Abstract][Full Text] [Related]
10. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591 [TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
12. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females. Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623 [TBL] [Abstract][Full Text] [Related]
13. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease. Sultan Y; Loyer F; Venot A Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100 [TBL] [Abstract][Full Text] [Related]
14. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome]. Fukao H; Yamamoto K; Matsuo O Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864 [TBL] [Abstract][Full Text] [Related]
15. A kinetic model of the circulatory regulation of tissue plasminogen activator. Chandler WL Thromb Haemost; 1991 Sep; 66(3):321-8. PubMed ID: 1746003 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431 [TBL] [Abstract][Full Text] [Related]
17. Blood fibrinolysis and the response to desmopressin in glomerulonephritis. Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642 [TBL] [Abstract][Full Text] [Related]
18. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma. Sørensen JV Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044 [TBL] [Abstract][Full Text] [Related]
19. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
20. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]